As of 2025-09-16, the EV/EBITDA ratio of Myriad Genetics Inc (MYGN) is -38.10. EV/EBITDA ratio is calculated by dividing the enterprise value by the TTM EBITDA. MYGN's latest enterprise value is 739.12 mil USD. MYGN's TTM EBITDA according to its financial statements is -19.40 mil USD. Dividing these 2 quantities gives us the above MYGN EV/EBITDA ratio.
Note: valuation result may not be accurate due to the company's negative EBITDA.
| Range | Selected | |
| Trailing P/E multiples | 11.3x - 15.8x | 14.5x |
| Forward P/E multiples | 12.8x - 16.7x | 14.4x |
| Fair Price | (3.30) - (3.92) | (3.65) |
| Upside | -145.1% - -153.7% | -149.9% |
| Date | EV/EBITDA |
| 2025-09-12 | -37.76 |
| 2025-09-11 | -39.87 |
| 2025-09-10 | -36.13 |
| 2025-09-09 | -36.47 |
| 2025-09-08 | -36.18 |
| 2025-09-05 | -34.74 |
| 2025-09-04 | -35.61 |
| 2025-09-03 | -35.65 |
| 2025-09-02 | -36.13 |
| 2025-08-29 | -33.59 |
| 2025-08-28 | -32.87 |
| 2025-08-27 | -31.48 |
| 2025-08-26 | -30.91 |
| 2025-08-25 | -31.29 |
| 2025-08-22 | -31.91 |
| 2025-08-21 | -31.00 |
| 2025-08-20 | -29.56 |
| 2025-08-19 | -29.47 |
| 2025-08-18 | -30.43 |
| 2025-08-15 | -30.43 |
| 2025-08-14 | -31.29 |
| 2025-08-13 | -31.19 |
| 2025-08-12 | -31.96 |
| 2025-08-11 | -32.73 |
| 2025-08-08 | -33.35 |
| 2025-08-07 | -32.30 |
| 2025-08-06 | -30.23 |
| 2025-08-05 | -21.60 |
| 2025-08-04 | -22.13 |
| 2025-08-01 | -21.79 |
| 2025-07-31 | -21.46 |
| 2025-07-30 | -22.46 |
| 2025-07-29 | -22.70 |
| 2025-07-28 | -24.05 |
| 2025-07-25 | -24.38 |
| 2025-07-24 | -25.34 |
| 2025-07-23 | -25.77 |
| 2025-07-22 | -25.05 |
| 2025-07-21 | -24.38 |
| 2025-07-18 | -24.48 |
| 2025-07-17 | -26.16 |
| 2025-07-16 | -27.31 |
| 2025-07-15 | -27.02 |
| 2025-07-14 | -28.08 |
| 2025-07-11 | -28.65 |
| 2025-07-10 | -29.42 |
| 2025-07-09 | -30.47 |
| 2025-07-08 | -29.66 |
| 2025-07-07 | -28.41 |
| 2025-07-03 | -29.90 |